Chinese clinical-stage biopharmaceutical firm JW Therapeutics on Wednesday announced the completion of a $100 million Series B round of financing led by alternative asset manager CPE and South Korea’s Mirae Asset.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
